Long-term tolerability of lamotrigine: Data from a 6-year continuation study

Epilepsy and Behavior

Volumn 5, Issue 1, 2004, Pages 31-36

  Faught, Edward ^a   Matsuo, Fumisuke U ^b   Schachter, Steven ^c   Messenheimer, John ^d   Womble, Gilda P ^d  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Adverse long term; Epilepsy; Lamotrigine; Partial seizures; Rash; Tolerability; Treatment

Indexed keywords

LAMOTRIGINE; PLACEBO; ANTICONVULSIVE AGENT; TRIAZINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; AMBLYOPIA; ARTICLE; CARDIOPULMONARY ARREST; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPTIC STATE; FEMALE; FOCAL EPILEPSY; HEADACHE; HEART INFARCTION; HUMAN; INJURY; LONG TERM CARE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PARALLEL DESIGN; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; TRAFFIC ACCIDENT; URTICARIA; COMPARATIVE STUDY; DEMOGRAPHY; DRUG INTERACTION; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; LONGITUDINAL STUDY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

ADULT; ANTICONVULSANTS; CROSS-OVER STUDIES; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG TOLERANCE; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES;

EID: 1542318169     PISSN: 15255050     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yebeh.2003.10.011     Document Type: Article

References (24)

1. Jawad S. Richens A. et al Controlled trial of lamotrigine (Lamictal) for refractory partial seizures Epilepsia 30 1989 356-363
2. Sander J.W.A.S. Patsalos P.N. Oxley J.R et al. A randomized, double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy Epilepsy Res. 6 1990 221-226
3. Loiseau P. Yuen A.W.C. Duche B. et al. A randomized double-blind crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures Epilepsy Res. 7 1990 136-145
4. Schapel G.J. Beran R.G. Vajda F.J.E. et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant partial seizures J. Neurol. Neurosurg. Psychiatry 56 1993 448-453
5. Matsuo F. Bergen D. Faught E. et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures Neurology 43 1993 2284-2291
6. Messenheimer J.A. Ramsay R.E. Willmore L.J. et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial Epilepsia 35 1994 1113-1121
7. Matsuo F. Lamotrigine Epilepsia 40 Suppl 5 1999 S30-S36
8. Gilliam F. Vazquez B. Sackellares J.C. et al. An active-control trial of lamotrigine monotherapy for partial seizures Neurology 51 1998 1018-1025
9. Brodie M.J. Richens A. Yuen A.W.C. et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy Lancet 345 1995 476-479
10. Steiner T.J. Dellaportas C.I. Findley L.J. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin Epilepsia 40 1999 601-607
11. Buoni S. Grosso S. Fois A. Lamotrigine in typical absence epilepsy Brain Dev. 21 1999 303-306
12. Motte J. Trevathan E. Arvidsson J.F.V. et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome N. Engl. J. Med. 337 1998 1807-1812
13. Messenheimer J.A. Mullens E.L. Giorgi L et al. Safety review of adult clinical trial experience with lamotrigine Drug Saf. 18 1998 281-296
14. Uvebrant P. Bauzien P.R. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits Neuropediatrics 25 1994 284-289
15. Frank L.M. Enlow T. Holmes G.L. et al. Lamictal monotherapy for typical absence seizures in children Epilepsia 40 1999 973-979
16. Schachter S.C. Leppik I.E. Matsuo F. et al. A six-month, placebo-controlled safety and tolerance study J. Epilepsy 8 1995 201-209
17. Matsuo F. Gay P. Madsen J et al. Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, 11-week study Epilepsia 37 1996 857-862
18. Biton V. Mirza W. Montouris G. et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy Neurology 56 2001 172-177
19. Devinsky O. Vuong A. Hammer A. Barrett P. Stable weight during lamotrigine therapy: a review of 32 studies Neurology 54 2000 973-975
20. Guberman A.H. Besag F.M.C. Brodie M.J. et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children Epilepsia 40 1999 985-991
21. Mackay F.J. Wilton L.V. Pearce G.L. et al. Safety of long-term lamotrigine in epilepsy Epilepsia 38 1997 881-886
22. Wong I.C. Mawer G.E. Sander J.W. Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom Epilepsia 42 2001 237-244
23. Messenheimer J.A. Rash in adult and pediatric patients treated with lamotrigine Can J. Neurol. Sci. 25 1998 S14-S18
24. Lamictal® (lamotrigine) Tablets Prescribing Information. GlaxoSmithKline, June 2003